Skip to Main Content

Paper Details

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
J Clin Lipidol
6
2022
Author NameAffiliation
Prakriti GabaBrigham and Women's Hospital, Harvard Medical School
Deepak L BhattBrigham and Women's Hospital, Harvard Medical School
  • 1 - 2

Datasets

Release 1.2